Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
about
Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse modelAn EGR2/CITED1 transcription factor complex and the 14-3-3sigma tumor suppressor are involved in regulating ErbB2 expression in a transgenic-mouse model of human breast cancerHeregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor familyIsolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumorsTReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domainThe N-terminal 24 amino acids of the p55 gamma regulatory subunit of phosphoinositide 3-kinase binds Rb and induces cell cycle arrestOncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gammaMechanism of activation of the human trk oncogeneMedullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behaviorProlonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neuUse of mRNA- and protein-destabilizing elements to develop a highly responsive reporter systemUpdate on HER-2 as a target for cancer therapy: the ERBB2 promoter and its exploitation for cancer treatmentERBB2 in cat mammary neoplasias disclosed a positive correlation between RNA and protein low expression levels: a model for erbB-2 negative human breast cancerDesigning a HER2/neu promoter to drive alpha1,3galactosyltransferase expression for targeted anti-alphaGal antibody-mediated tumor cell killing.The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitorRole of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review)Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformationAnti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomasHuman breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapyA chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products.Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor alpha in NIH 3T3 cellsPhosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors.Antibody-conjugated gold-gold sulfide nanoparticles as multifunctional agents for imaging and therapy of breast cancer.Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation.Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.Ligand-directed retroviral targeting of human breast cancer cells.Antisense DNA downregulation of the ERBB2 oncogene measured by a flow cytometric assay.Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationshipsA cancer-specific transcriptional signature in human neoplasia.Dual-wavelength imaging of tumor progression by activatable and targeting near-infrared fluorescent probes in a bioluminescent breast cancer model.Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides.
P2860
Q22064565-D9AC6B3E-D873-4608-8773-F069302A2533Q24297853-874672D3-3D2A-4A2C-A17E-69AB490556F6Q24309266-90B7AD68-3AFA-499F-A0BB-6534B331173CQ24314750-241A03EF-3E87-4FC6-8926-2AF0AF165135Q24339400-4193EF06-6B31-4B0E-9631-2D1AF126320EQ24529076-0C4EF235-2896-4D77-ACB4-45717841D170Q24551173-AF9EB99C-52BC-425F-AC6B-028C7FCA0549Q24554327-B67EA85E-BB5D-49EB-ABDC-6DC273EF1450Q24561375-68C0C6FC-A3AB-4E60-9DA0-BE8755C3281DQ24594163-0D8296D8-8584-45AD-9B23-9A7A950A7D52Q24676403-415303EB-1B2C-425F-8361-4DA16AD00A80Q24685875-118DC732-EC83-4BF2-A289-BAD826DA2A8BQ24791989-68CF03C9-2AB1-4A20-AC85-182BB7AD1098Q24801967-88C3EE56-1C19-4960-96B9-BB6CFDFE7B57Q24810389-AF1420A3-CBF2-42A2-A131-6853F5912C47Q24810669-A8ADDE72-C648-45CD-811E-55B3294E5DADQ28118420-BB6DBE90-5CA6-4C45-9D22-4E41A09F7CA2Q28394917-60E7FFD9-C56C-4BB4-A312-E792B3C691E6Q28570541-B9E97008-E073-44AB-BF4A-0BBAB8BB21C4Q29398901-1DCDFBB8-1C0B-42A3-A4DF-FF1D46FEF2EDQ30412654-D90A7A51-2927-4251-BC89-557FF885E3EDQ33235035-54B6F6AE-1B5A-42F7-97B9-11F62D91746BQ33353929-FE2FC48F-210C-46EC-BE8F-A862DEB8A089Q33557958-3B8269F0-E401-41A8-95DE-8BFC7FEC4E95Q33630332-EF9BEF59-AD54-45ED-8A7A-ADAD39241417Q33632011-E5A80223-5DEB-4CAC-AB2E-CCA6983F227FQ33634356-FE20D122-0A69-4A11-A580-A930665EF116Q33651125-78A2296B-EC12-454A-884D-A92184536473Q33670296-CC1F9346-FC09-412C-BDFB-A7BCEF0AA0E0Q33722013-7AF718F7-EDED-48A6-B178-0F7B9E158227Q33849412-8DD85277-2647-4431-860B-7B09EFE1C348Q33852935-AF68A92B-3EAE-4978-A5B5-D1CBAC8AFEA7Q33868131-65B72BCA-5E46-4181-BFF7-10531786296CQ33970193-29CB0D57-DB1D-447C-AE82-277A51A38A16Q34045509-6B15E4BD-F604-4650-8BBF-4A03914C1822Q34078670-1A45288E-1BB4-4BAD-BD0F-6EAC816E6CF7Q34163763-412C6369-D6DF-4FC2-B1D5-02B564F2B3C8Q34353519-861396FB-2408-4F0D-A148-E4A8368751BBQ34381218-A4995B6A-7609-4847-881F-DBD41930E413Q34618574-38700004-C830-4CC5-AF79-C86A051F0C94
P2860
Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
description
1987 nî lūn-bûn
@nan
1987 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի մարտին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Overexpression of the EGF rece ...... different molecular mechanisms
@ast
Overexpression of the EGF rece ...... different molecular mechanisms
@en
type
label
Overexpression of the EGF rece ...... different molecular mechanisms
@ast
Overexpression of the EGF rece ...... different molecular mechanisms
@en
prefLabel
Overexpression of the EGF rece ...... different molecular mechanisms
@ast
Overexpression of the EGF rece ...... different molecular mechanisms
@en
P2093
P2860
P1433
P1476
Overexpression of the EGF rece ...... different molecular mechanisms
@en
P2093
P2860
P304
P356
10.1002/J.1460-2075.1987.TB04797.X
P407
P577
1987-03-01T00:00:00Z